Description Effect and benefit Mechanism of action Safety Pharmacology
ChemicalBook > CAS DataBase List > Entrectinib

Entrectinib

Description Effect and benefit Mechanism of action Safety Pharmacology
Entrectinib Structure
Entrectinib
  • CAS No.1108743-60-7
  • Chemical Name:Entrectinib
  • CBNumber:CB93040787
  • Molecular Formula:C31H34F2N6O2
  • Formula Weight:560.64
  • MOL File:1108743-60-7.mol
Entrectinib Property
  • Boiling point: :717.5±60.0 °C(Predicted)
  • Density  :1.340±0.06 g/cm3(Predicted)
  • pka :12.01±0.43(Predicted)
  • FDA UNII :L5ORF0AN1I
  • NCI Dictionary of Cancer Terms :entrectinib
  • NCI Drug Dictionary :entrectinib
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal word
  • Hazard statements
  • Precautionary statements
Entrectinib Price More Price(3)
  • Brand: Cayman Chemical
  • Product number: 19476
  • Product name : Entrectinib
  • Purity: ≥98%
  • Packaging: 1mg
  • Price: $28
  • Updated: 2021/03/22
  • Buy: Buy
  • Brand: Cayman Chemical
  • Product number: 19476
  • Product name : Entrectinib
  • Purity: ≥98%
  • Packaging: 5mg
  • Price: $98
  • Updated: 2021/03/22
  • Buy: Buy
  • Brand: Cayman Chemical
  • Product number: 19476
  • Product name : Entrectinib
  • Purity: ≥98%
  • Packaging: 10mg
  • Price: $182
  • Updated: 2021/03/22
  • Buy: Buy

Entrectinib Chemical Properties,Usage,Production

  • Description Entrectinib is used to treat metastatic (lung cancer that has already spread) non-small cell lung cancer (NSCLC) that is caused by a gene called ROS1. This medicine is also used to treat solid tumors (cancer) that are caused by certain abnormal NTRK genes and have spread or if surgery to remove the cancer is likely to cause severe complications, and there is no acceptable treatment option or the cancer grew or spread on other treatments.
  • Effect and benefit Entrectinib belongs to the group of medicines called antineoplastics (cancer medicines). It works by interfering with the growth of cancer cells, which are eventually destroyed.
  • Mechanism of action An inhibitor of tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC (encoded by the neurotrophic tyrosine receptor kinase [NTRK] genes NTRK1, NTRK2, and NTRK3, respectively), proto-oncogene tyrosine-protein kinase ROS1 (ROS1), and anaplastic lymphoma kinase (ALK); also, inhibits JAK2 and TNK2. Major active metabolite of entrectinib, M5, showed similar in vitro activity against TRK, ROS1, and ALK. Fusion proteins that include TRK, ROS1, or ALK kinase domains can drive tumorigenic potential through hyperactivation of downstream signaling pathways, leading to unconstrained cell proliferation.
  • Safety Entrectinib exhibits hepatic metabolism through cytochrome P450 (CYP) 3A and therefore interacts with moderate-strong CYP3A inhibitors and inducers. In addition, due to its effects on the QTcF interval, use of entrectinib should be avoided with other drugs known to prolong the QT/QTc interval.
  • Pharmacology Entrectinib, is a weak P-gp substrate that can sustain CNS exposure based on our novel in vitro and in vivo experiments. This is consistent with the observed preclinical and clinical efficacy of entrectinib in neurotrophic tropomyosin receptor kinase (NTRK) and ROS1 fusion-positive CNS tumors and secondary CNS metastases.
  • Description Entrectinib (RXDX-101, Ignyta Pharmaceuticals, San Diego, CA, USA) is a small molecule that inhibits the tyrosine kinases TRKA/B/C, ROS1, and ALK (Table?1). It has a preclinical median inhibitory concentration (IC50) of 7?nm against ROS1, higher than crizotinib [95, 96]. Entrectinib was specifically designed to cross the blood-brain barrier [95].
  • Clinical Use Entrectinib demonstrated potent antitumor effects in tumor cell lines and patient-derived xenograft (PDX) tumor models in preclinical studies. Furthermore, entrectinib can cross the blood–brain barrier (BBB) to impact primary brain tumors and brain metastases in patients with NTRK1/ NTRK2/NTRK3, ROS1, and ALK fusion-driven cancers.
Entrectinib Preparation Products And Raw materials
Raw materials
Preparation Products
Global(127)Suppliers
  • Supplier:
    ATK CHEMICAL COMPANY LIMITED
  • Tel:+86 21 5161 9050/ 5187 7795
  • Fax:+86 21 5161 9052/ 5187 7796
  • Email:ivan@atkchemical.com
  • Country:CHINA
  • ProdList:26725
  • Advantage:60
  • Supplier:
    career henan chemical co
  • Tel:+86-371-86658258
  • Fax:
  • Email:sales@coreychem.com
  • Country:CHINA
  • ProdList:29970
  • Advantage:58
  • Supplier:
    TianYuan Pharmaceutical CO.,LTD
  • Tel:+86-755-23284190 13684996853
  • Fax:+86-755-23284190
  • Email:sales@tianpharm.com
  • Country:CHINA
  • ProdList:305
  • Advantage:58
  • Supplier:
    Biochempartner
  • Tel:0086-13720134139
  • Fax:
  • Email:candy@biochempartner.com
  • Country:CHINA
  • ProdList:968
  • Advantage:58
  • Supplier:
    BOC Sciences
  • Tel:1-631-485-4226
  • Fax:1-631-614-7828
  • Email:inquiry@bocsci.com
  • Country:United States
  • ProdList:19753
  • Advantage:58
  • Supplier:
    Chongqing Chemdad Co., Ltd
  • Tel:+86-13650506873
  • Fax:
  • Email:sales@chemdad.com
  • Country:CHINA
  • ProdList:37282
  • Advantage:58
  • Supplier:
    Alchem Pharmtech,Inc.
  • Tel:8485655694
  • Fax:
  • Email:sales@alchempharmtech.com
  • Country:United States
  • ProdList:63726
  • Advantage:58
  • Supplier:
    Target Molecule Corp
  • Tel:18019718960 781-999-5354
  • Fax:
  • Email:marketing@targetmol.com
  • Country:United States
  • ProdList:19232
  • Advantage:58
Related articles
1108743-60-7, EntrectinibRelated Search:
  • N-[5-[(3,5-Difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]benzamide
  • Entrectinib
  • Entrectinib(NMS-E628)
  • N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide
  • RXDX-101
  • Entrectinib,NMS-E628,RXDX-101
  • entrecitinib
  • Entrectinib(RXDX-101)
  • NMS-E628
  • CS-1589
  • NMS E628; RXDX-101;NMSE628; RXDX 101;NMS-E628; RXDX101
  • RXDX101; RXDX 101; RXDX-101; NMS E628; NMSE628; NMS-E628; ENTRECTINIB
  • Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-
  • 1108743-60-7
  • C31H34F2N6O2
  • API
  • API